image credit: Adobe Stock

Verona cues up filings for COPD drug after it aces phase 3 test

August 9, 2022

The drug was administered twice-daily using a nebuliser as a chronic maintenance therapy for people with COPD in the ENHANCE-2 study, cutting the rate of moderate to severe exacerbations – sudden worsening of COPD symptoms – by 42% over 24 weeks.

Ensifentrine also achieved significant improvements in key measures of lung function in the trial, including the primary endpoint of forced expiratory volume (FEV1) at 12 weeks, as well as in COPD symptom scores, with safety results “similar to placebo.”

Read More on Pharmaphorum